With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII
After setting up one biotech company with a drug plucked from the shelves of big pharma, the same team is doing it again.
Provention Bio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
